Miglustat

Drug Profile

Miglustat

Alternative Names: Brazaves; NB-DNJ; OGT 918; OXAIDS; SC 48334; Zavesca

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Oxford Glycobiology Institute
  • Developer Actelion Pharmaceuticals; National Taiwan University; Teva Pharmaceutical Industries; United Therapeutics Corporation
  • Class Alkaloids; Imino pyranoses; Small molecules
  • Mechanism of Action Alpha-glucosidase inhibitors; Glucosylceramide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gaucher's disease type I; Niemann-Pick diseases
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gaucher's disease type I; Niemann-Pick diseases
  • Phase II Cystic fibrosis; Gaucher's disease type III
  • Preclinical Hepatitis C
  • Discontinued HIV infections; Tay-Sachs disease

Most Recent Events

  • 01 Jul 2015 Phase-II clinical trials in Gaucher's disease type III (Combination therapy) in Taiwan (PO) (NCT02520934)
  • 10 Apr 2015 Miglustat is still awaiting approval for Niemann-Pick disease in USA
  • 19 Jul 2012 Launched for Niemann-Pick disease in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top